News &
Events

 

Latest News

Ramot Newsletter December 2018

Read More

Ramot and BioNTech sign license agreement to use novel set of lipids for improved mRNA delivery

Ramot and BioNTech RNA Pharmaceuticals GmbH, a leader in the development of precise and individualized immunotherapies with a broad and rapidly growing clinical pipeline today announced, that they have entered into a license agreement to further explore a set of novel lipids for improved mRNA delivery in various therapeutic indications.

 

Read More

Drug candidate may recover vocal abilities lost to ADNP syndrome

Protein snippet normalizes disrupted neural connectivity caused by genetic disorder, Tel Aviv University researchers say

Read More

A JOINT RESEARCH COLLABORATION WITH A GLOBAL PHARMA COMPANY ON PROTEIN DEGRADATION PLATFORM

TEL AVIV, ISRAEL, October 8th, Tel Aviv University (TAU) through Ramot, its Business Engagement Center, announce the signing of a collaboration agreement with Novartis to explore several applications and uses of a novel platform for identified new targets and modulators of the ubiquitin pathways developed by Prof. Gali Prag from the TAU School of Neurobiology Biochemistry and Biophysics.

Read More